Performance of a second‐generation methylated SEPT9 test in detecting colorectal neoplasm
Authors:
- 4 December 2014
- journal article
- research article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 30 (5) , 830-833
Abstract
Background and Aim: Screening and early detection reduces mortality due to colorectal cancer (CRC). Methylated Septin 9 (SEPT9) is a new blood‐based biomarker for CRC. We evaluated the performance of the second‐generation SEPT9 assay for the detection of colorectal neoplasm, and compared it with fecal immunochemical test (FIT).Methods: A total of 135 patients with CRC, 169 with adenomatous polyps, 81 with hyperplastic polyps, and 91 healthy controls were included. The clinical status of all subjects was verified by colonoscopy. In all patients, peripheral blood samples were taken for SEPT9 testing using Epi proColon 2.0 test. For 177 patients, both SEPT9 and FIT were performed.Results: The sensitivity and specificity of SEPT9 for CRC were 74.8% (95% confidence interval [CI]: 67.0–81.6%) and 87.4% (vs non‐CRC, 95% CI: 83.5–90.6%), respectively. SEPT9 was positive in 66.7% of stage I, 82.6% of stage II, 84.1% of stage III, and 100% of stage IV CRCs. The sensitivity of SEPT9 for advanced adenomas was 27.4% (95% CI: 18.7–37.6%). The sensitivity and specificity of FIT for CRC was 58.0% (95% CI: 46.1–69.2%) and 82.4% (95% CI: 74.4–88.7%), respectively. SEPT9 showed better performance in CRC detection than FIT, but similar among advanced adenomas.Conclusions: With improved performance characteristics in detecting CRC, the second‐generation SEPT9 assay could play an important role in CRC screening and early detection.Keywords
Funding Information
- National High Technology Research and Development Program (863 Program) of China (SS2014AA020803)
This publication has 19 references indexed in Scilit:
- Aberrant septin 9 DNA methylation in colorectal cancer is restricted to a single CpG islandBMC Cancer, 2013
- Detection of Methylated SEPT9 in Plasma Is a Reliable Screening Method for Both Left- and Right-Sided Colon CancersPLOS ONE, 2012
- Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancerBMC Medicine, 2011
- Comparison of immunochemical and guaiac‐based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: A meta‐analysisJournal of Digestive Diseases, 2010
- Performance of Epigenetic Markers SEPT9 and ALX4 in Plasma for Detection of Colorectal Precancerous LesionsPLOS ONE, 2010
- Circulating Methylated SEPT9 DNA in Plasma Is a Biomarker for Colorectal CancerClinical Chemistry, 2009
- A Pooled Analysis of Advanced Colorectal Neoplasia Diagnoses After Colonoscopic PolypectomyGastroenterology, 2009
- Sensitive Detection of Colorectal Cancer in Peripheral Blood by Septin 9 DNA Methylation AssayPLOS ONE, 2008
- Screening for Colorectal Neoplasms With New Fecal Occult Blood Tests: Update on Performance CharacteristicsJNCI: Journal of the National Cancer Institute, 2007
- A Comparison of the Immunochemical Fecal Occult Blood Test and Total Colonoscopy in the Asymptomatic PopulationGastroenterology, 2005